STOP AT ONEではなく、STOP AT ZEROへ
患者さんの笑顔がみたいから ～骨粗鬆症の予防・治療の大切さ～
東京骨粗鬆症センター長 前田浩行
骨折を1回してから治療ではなく、骨折する前に動けなくなる前に早めに骨密度検査、専門外来を受診していただき早期発見、予防、治療につなげていきたいと考えています。当院は、東京骨粗鬆症センターを開設しました。
60歳を過ぎるとカルシウムをいくら取っても骨粗鬆症という病気になります。ご家族で骨折をした方や手術をした方がいるとそのお子さんも骨粗鬆症になり、骨折のリスクが高まるといわれています。早めに検査、治療をし予防をすることで寝たきりにならないようにしましょう。特に腰椎圧迫骨折、大腿骨骨折の患者さんは寝たきりになるリスクが高まり、ご家族の介護負担が大きくなります。骨粗鬆症学会認定医、整形外科学会専門医による専門外来を行っています。お気軽に受診下さい。骨粗鬆症治療を開始する前に、寝たきり予防ドックを受診することをお勧めいたします。
当院は国際骨粗鬆症財団から骨粗鬆症の啓発、予防、治療に積極的に取り組んだ団体として表彰を受けました。国際骨粗鬆症財団(IOF: International Osteoporosis Foundation)は骨粗鬆症の予防・啓発、治療などを世界で行っている財団です。骨粗鬆症は寝たきりになる怖い病気です。早期発見、早期治療、予防が大変重要です。積極的な骨粗鬆症専門検査をおねがいします。
当院の骨粗鬆症研究が、国際的に権威ある医学誌「JBMR Plus」に掲載されました
当院で行ったロモソズマブ（イベニティ®）再投与に関する研究が、骨・骨粗鬆症分野で国際的に高く評価されている医学誌「JBMR Plus」 に掲載されました。
JBMR Plusは、米国骨代謝学会（ASBMR）が発行する国際査読誌です。
当院の骨粗鬆症治療に関する研究成果が、世界に向けて発信される大きな成果となりました。
▶ 論文はこちら（JBMR Plus / Oxford Academic）
English Page
Advanced Osteoporosis Care at Maeda Hospital
Maeda Hospital provides specialized osteoporosis care in Higashikurume, Tokyo, Japan, with a strong focus on fracture prevention, long-term treatment adherence, and patient-centered education.
In recognition of our continuous efforts to improve osteoporosis awareness and treatment, including daily clinical practice, scientific publications, and presentations at academic conferences, our hospital received the Silver Award from the International Osteoporosis Foundation (IOF).
We actively use evidence-based osteoporosis therapies, including injectable medications, and carefully select the most appropriate treatment for each patient according to fracture risk, bone mineral density, age, lifestyle, and individual preferences.
A major focus of our practice is patient education. We explain not only the benefits of osteoporosis treatment, but also what may happen if osteoporosis is left untreated—including fractures, loss of mobility, becoming bedridden, and the need for long-term nursing care. By helping patients and their families understand the disease clearly, we aim to improve motivation and long-term continuation of therapy.
We also actively utilize patient-support programs, including the Re-Bone Club, which provides reminders and support for patients receiving self-injection therapy. Our hospital has achieved one of the highest levels of patient registration and participation in Japan.
In addition, we regularly hold approximately one-hour educational sessions for patients in our outpatient waiting area to improve their understanding of osteoporosis and strengthen their motivation to continue treatment.
We believe that effective osteoporosis care does not always require a large-scale liaison system. Even in a community hospital, dedicated physicians who provide careful explanations, respond promptly to patients’ concerns, and continue to support them throughout treatment can make a major difference in treatment persistence and fracture prevention.
Our clinical experience is also actively translated into academic research. We continue to publish original studies in international peer-reviewed medical journals and present our findings at scientific meetings, contributing real-world evidence from Japan to the global osteoporosis community.
Our goal is to provide osteoporosis treatment that brings confidence and hope to patients and their families. We carefully support each patient in selecting and continuing the most appropriate therapy, while working together with healthcare professionals and pharmaceutical companies to achieve the best possible outcomes.
Osteoporosis treatment can change a patient’s future.
We will continue striving to provide care that prevents fractures, preserves independence, and brings genuine happiness to our patients.
